MASS Quote, Financials, Valuation and Earnings

Repligen has a net margin of -103.33% compared to 908 Devices's net margin of -20.22%. 908 Devices's return on equity of -49.84% beat Repligen's return on equity of -1.29%.

908 Devices has a consensus price target of $6.00, signalling upside risk potential of 41.03%. On the other hand Repligen has an analysts' consensus of $190.47 which suggests that it could grow by 45.48%. Given that Repligen has higher upside potential than 908 Devices, analysts believe Repligen is more attractive than 908 Devices.

908 Devices has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Repligen has a beta of 1.266, suggesting its more volatile than the S&P 500 by 26.606%.

908 Devices has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Repligen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. 908 Devices pays -- of its earnings as a dividend. Repligen pays out -- of its earnings as a dividend.

908 Devices quarterly revenues are $18.8M, which are smaller than Repligen quarterly revenues of $167.5M. 908 Devices's net income of -$19.4M is higher than Repligen's net income of -$33.9M. Notably, 908 Devices's price-to-earnings ratio is -- while Repligen's PE ratio is 633.44x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for 908 Devices is 2.23x versus 11.61x for Repligen. Usually stocks with elevated PS ratios are considered overvalued.

VolitionRX has a net margin of -103.33% compared to 908 Devices's net margin of -1226.82%. 908 Devices's return on equity of -49.84% beat VolitionRX's return on equity of --.

908 Devices has a consensus price target of $6.00, signalling upside risk potential of 41.03%. On the other hand VolitionRX has an analysts' consensus of $3.37 which suggests that it could grow by 523.88%. Given that VolitionRX has higher upside potential than 908 Devices, analysts believe VolitionRX is more attractive than 908 Devices.

908 Devices has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison VolitionRX has a beta of 1.155, suggesting its more volatile than the S&P 500 by 15.463%.

908 Devices has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. 908 Devices pays -- of its earnings as a dividend. VolitionRX pays out -- of its earnings as a dividend.

908 Devices quarterly revenues are $18.8M, which are larger than VolitionRX quarterly revenues of $474.5K. 908 Devices's net income of -$19.4M is lower than VolitionRX's net income of -$5.8M. Notably, 908 Devices's price-to-earnings ratio is -- while VolitionRX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for 908 Devices is 2.23x versus 34.90x for VolitionRX. Usually stocks with elevated PS ratios are considered overvalued.

Catheter Precision has a net margin of -103.33% compared to 908 Devices's net margin of -4291.67%. 908 Devices's return on equity of -49.84% beat Catheter Precision's return on equity of -65.84%.

908 Devices has a consensus price target of $6.00, signalling upside risk potential of 41.03%. On the other hand Catheter Precision has an analysts' consensus of -- which suggests that it could grow by 484.8%. Given that Catheter Precision has higher upside potential than 908 Devices, analysts believe Catheter Precision is more attractive than 908 Devices.

908 Devices has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Catheter Precision has a beta of -0.775, suggesting its less volatile than the S&P 500 by 177.508%.

908 Devices has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catheter Precision offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. 908 Devices pays -- of its earnings as a dividend. Catheter Precision pays out -- of its earnings as a dividend.

908 Devices quarterly revenues are $18.8M, which are larger than Catheter Precision quarterly revenues of $96K. 908 Devices's net income of -$19.4M is lower than Catheter Precision's net income of -$4.1M. Notably, 908 Devices's price-to-earnings ratio is -- while Catheter Precision's PE ratio is 0.40x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for 908 Devices is 2.23x versus 0.91x for Catheter Precision. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of -103.33% compared to 908 Devices's net margin of -10.04%. 908 Devices's return on equity of -49.84% beat Xtant Medical Holdings's return on equity of -35.34%.

908 Devices has a consensus price target of $6.00, signalling upside risk potential of 41.03%. On the other hand Xtant Medical Holdings has an analysts' consensus of $1.75 which suggests that it could grow by 272.34%. Given that Xtant Medical Holdings has higher upside potential than 908 Devices, analysts believe Xtant Medical Holdings is more attractive than 908 Devices.

908 Devices has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of -0.033, suggesting its less volatile than the S&P 500 by 103.341%.

908 Devices has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. 908 Devices pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

908 Devices quarterly revenues are $18.8M, which are smaller than Xtant Medical Holdings quarterly revenues of $31.5M. 908 Devices's net income of -$19.4M is lower than Xtant Medical Holdings's net income of -$3.2M. Notably, 908 Devices's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for 908 Devices is 2.23x versus 0.54x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.